FDA Panel Loosens Noose on Avandia

(MedPage Today) -- SILVER SPRING, Md. -- A panel of FDA advisers thinks it is time to ease restrictions on access to Avandia (rosiglitazone), a onetime multimillion dollar blockbuster drug brought low by reports that it increased the risk of heart attacks.
Source: MedPage Today Geriatrics - Category: Geriatrics Source Type: news